Chemed Corporation (CHE) Guidance & Earnings Results

On 2026-07-28 Chemed Corporation raised guidance: "FY26 adjusted EPS raised to $25.00-$25.75 from $24.00-$24.75; Roto-Rooter FY26 revenue growth 3.0%-3.5%, adjusted EBITDA margin…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CHEChemed CorporationFollow CHE — free

Medical Care Facilities · Healthcare

—

Price chart with a free account

Market cap: 6.7B
P/E TTM: 25.8
Dividend yield: 0.5%
52-week: —
Next earnings: 27 Oct, in 3 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
28 Jul 26	Raised	FY26 adjusted EPS raised to $25.00-$25.75 from $24.00-$24.75; Roto-Rooter FY26 revenue growth 3.0%-3.5%, adjusted EBITDA margin 21.5%-22.5% · full year
23 Apr 26	Raised	Full-year guidance raised due to strong VITAS performance and share repurchases · full year
25 Feb 26	Raised	2026 adjusted EPS guidance $23.25-$24.25 vs $21.55 in 2025, implying 8-13% growth · full year
28 Oct 25	Reaffirmed	$22.00 to $22.30 per share · full year
29 Jul 25	Lowered	FY25 adjusted EPS cut to $22.00-22.30 from $24.95-25.45; VITAS revenue +7.5-8.5% (prior not given), EBITDA margin 18.2-18.7% ex-cap; Roto-Rooter revenue +1.25-1.75%, EBITDA margin 23.5-24.5% · full year

Chemed Corporation — questions

What guidance did Chemed Corporation give?: On 2026-07-28: "FY26 adjusted EPS raised to $25.00-$25.75 from $24.00-$24.75; Roto-Rooter FY26 revenue growth 3.0%-3.5%, adjusted EBITDA margin 21.5%-22.5%"
When does Chemed Corporation report earnings?: Chemed Corporation's next earnings report is expected on 2026-10-27.

Every figure on this page comes from Chemed Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.